S.Korea, Japan compete in gastroesophageal reflux drug market

HK Inno.N and Daewoong Pharmaceutical are challenging the Tokyo-based Takeda Pharmaceutical, the global market leader

HK inno.N's K-Cab (left) and Daewoong Pharma's Fexuclu
HK inno.N's K-Cab (left) and Daewoong Pharma's Fexuclu
Ji-Hyun Lee 1
2023-01-27 11:19:36 bluesky@hankyung.com
Bio & Pharma

South Korea is battling Japan again, this time on the global market to treat gastroesophageal reflux disease (GERD).

South Korea's pharmaceutical product maker HK Inno.N is expanding the number of licensing offices for its GERD drug K-Cab, and Daewoong Pharmaceutical is doing the same for its Fexuclu medicine to take on the global market leader Taekcab made by Takeda Pharmaceutical of Japan.

HK Inno.N on Thursday said it recently signed a contract with Europharma, a Brazilian pharmaceutical corporation, to export K-Cab technology. The former will transfer manufacturing technology and know-how to the latter, and Europharma will oversees product development and sales in Brazil for 10 years.

Releasing the value of an export contract for pharmaceutical technology is standard, but not for this deal. Europharma requested that such information remain confidential because doing so will help the company gain a competitive edge against Brazilian market leader Takecab.

Through its technology transfer deal in Brazil, HK Inno.N has laid the foundation for supplying K-Cab throughout the Americas. The Brazilian market for peptic ulcer medicine in 2020 was worth 800 billion won ($651 million), sixth in the world and No. 1 in South America.

HK Inno.N first launched K-Cab in China and the Philippines and seeks to export the drug to 100 countries by 2028.

On the same day, Daewoong Pharmaceutical said it applied for approval of Fexuclu with the Food and Drug Authority of Saudi Arabia, the 11th country where the company has filed such an application under its goal to sell the drug in 20 countries by 2025.

In 2021, the peptic ulcer medicine market in Saudi Arabia was worth 410 billion won, ranking 12th worldwide and No. 1 in the Middle East.

Write to Ji-Hyun Lee at bluesky@hankyung.com
#gastroesophageal reflux disease (GERD) #Korea #HK Inno.N #Daewoong Pharmaceutical #Japan #Takeda Pharmaceutical

HK inno.N to introduce biosimilars for bone disease treatment from Spain

HK inno.N to introduce biosimilars for bone disease treatment from Spain

South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to introduce biosimilars of bone loss treatment Prolia and Xgeva.Under the terms of the agreement, HK inno.N plans to apply for permits by acquiring dome

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharma's botulinum toxin Nabota wins approval from Australia

Daewoong Pharmaceutical said on Wednesday that its botulinum toxin formulation Nabota (overseas brand name: Nuceiva) won approval in Australia on Jan. 13.The item that received approval this time is Nuceiva 100 units whose application to the Australian authorities had been made by Nabota's cos

Daewoong submits new drug applications for Fexuclue in 10 countries

Daewoong submits new drug applications for Fexuclue in 10 countries

Daewoong's new GERD drug Fexuclue South Korea's leading drug company Daewoong Pharmaceutical is accelerating its global expansion efforts for its 34th domestically developed drug Fexuclue (active ingredient: Fexuprazan).The company said on Wednesday that it has submitted new drug applications (

HK inno.N’s K-CAB a blockbuster drug with $843 million exports

HK inno.N’s K-CAB a blockbuster drug with $843 million exports

HK inno.N's K-CAB, a gastroesophageal reflux disease (GERD) treatment drug South Korea’s HK inno.N Corp. has signed a 640 billion won ($540 million) contract to license out its technology for K-CAB, a gastroesophageal reflux disease drug, to Braintree Laboratories Inc., a subsidiary of US
(* comment hide *}